LENSᵃⁱ Update: IPA’s BioStrand LENSᵃⁱ™ integrates advanced HYFT^® technology to enhance LLMs and accelerate antibody discovery.

Dr. Dirk Van Hyfte, Head of Innovation and Co-Founder at BioStrand, stated, “The integration of HYFT technology into our LLMs marks a transformative moment in biotechnology." See full announcement